Prospective study of autism phenomenology and the behavioural phenotype of Phelan–McDermid syndrome: comparison to fragile X syndrome, Down syndrome and idiopathic autism spectrum disorder
Tóm tắt
The limited behavioural phenotype literature on Phelan–McDermid syndrome (PMS) indicates atypically high levels of activity, impulsivity and autism spectrum disorder (ASD) behaviours. Divergent profiles of ASD in PMS are also reported, with some studies demonstrating similarities to idiopathic ASD and others indicating an uneven profile of social and communication impairments and repetitive behaviours. An evaluation of the behavioural phenotype of PMS and the prevalence and phenomenology of ASD is warranted, particularly given the causal involvement of the SHANK3 gene in the aetiology of PMS. Carers of individuals with PMS (N = 30; mean age = 10.55, SD = 7.08) completed questionnaires relating to impulsivity, overactivity, mood, interest and pleasure, repetitive behaviour and ASD phenomenology. These data were compared to data from matched samples of individuals with fragile X and Down syndromes and idiopathic ASD. In order to evaluate the profile of ASD phenomenology in PMS, two comparisons were made: first, including the total sample with PMS, and second, including only those who met the threshold indicative of autism on an ASD screening measure. The results revealed lower mood in individuals with PMS, but no differences in impulsivity and overactivity. Compulsive and routine-driven repetitive behaviours were less common in the total sample with PMS; however, motor-based stereotyped behaviours were more common. ASD phenomenology was highly prevalent, with 87% of the sample meeting the cutoff score for ASD and 57% meeting the cutoff for autism. The profile of ASD phenomenology in the total sample with PMS differed from those with idiopathic ASD across impairments in communication and social interaction and repetitive behaviour. However, the profile of those who met the threshold for autism was commensurate to those with idiopathic ASD. ASD phenomenology is common within PMS. Whilst the total sample may display an atypical profile of ASD behaviour, the profile in those who met the threshold for autism was very similar to those with idiopathic ASD. These results are discussed in relation to the wider behavioural phenotype and the emerging evidence of an autism endophenotype in PMS.
Từ khóa
Tài liệu tham khảo
Phelan MC. Deletion 22q13. 3 syndrome. Orphanet J Rare Dis. 2008;3:7.
Phelan MC, Rogers RC, Saul RA, Stapleton GA, Sweet K, McDermid H, et al. 22q13 deletion syndrome. Am J Med Genet. 2001;101:91–9.
Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F, et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet. 2006;39:25–7.
Phelan K, McDermid HE. The 22q13. 3 deletion syndrome (Phelan-McDermid syndrome). Mol Syndromol. 2011;2:186–201.
Wilson HL, Wong ACC, Shaw SR, Tse WY, Stapleton GA, Phelan MC, et al. Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. J Med Genet. 2003;40:575–84.
Monteiro P, Feng G. SHANK proteins: roles at the synapse and in autism spectrum disorder. Nat Rev Neurosci. 2017;18:147–57.
Yi F, Danko T, Botelho SC, Patzke C, Pak C, Wernig M, Südhof TC. Autism-associated SHANK3 haploinsufficiency causes Ih channelopathy in human neurons. Science. 2016;352:aaaf2669-1-10.
Luciani JJ, De Mas P, Depetris D, Mignon-Ravix C, Bottani A, Prieur M, et al. Telomeric 22q13 deletions resulting from rings, simple deletions, and translocations: cytogenetic, molecular, and clinical analyses of 32 new observations. J Med Genet. 2003;40:690–6.
Havens JM, Visootsak J, Phelan MC, Graham JM. 22q13 deletion syndrome: an update and review for the primary pediatrician. Clin Pediatr. 2004;43:43–53.
Zwanenburg RJ, Ruiter SA, van den Heuvel ER, Flapper BC, Van Ravenswaaij-Arts CM. Developmental phenotype in Phelan-McDermid (22q13. 3 deletion) syndrome: a systematic and prospective study in 34 children. J Neurodev Disord. 2016;8:1.
Shaw SR, Rahman A, Sharma A. Behavioral profiles in Phelan-McDermid syndrome: focus on mental health. J Ment Health Res Intellect Disabil. 2011;4:1–18.
Jeffries AR, Curran S, Elmslie F, Sharma A, Wenger S, Hummel M, Powell J. Molecular and phenotypic characterization of ring chromosome 22. Am J Med Genet Part A. 2005;137:139–47.
Verhoeven WM, Egger JI, Willemsen MH, de Leijer GJ, Kleefstra T. Phelan-McDermid syndrome in two adult brothers: atypical bipolar disorder as its psychopathological phenotype? Neuropsychiatr Dis Treat. 2012;8:175.
Soorya L, Kolevzon A, Zweifach J, Lim T, Dobry Y, Schwartz L, et al. Prospective investigation of autism and genotype-phenotype correlations in 22q13 deletion syndrome and SHANK3 deficiency. Mol Autism. 2013;4:18.
Kolevzon A, Angarita B, Bush L, Wang AT, Frank Y, Yang A, Rapaport R, Saland J, Srivastava S, Farrell C, Edelmann LJ. Phelan-McDermid syndrome: a review of the literature and practice parameters for medical assessment and monitoring. J Neurodev Disord. 2014;6:39.
Bill BR, Geschwind DH. Genetic advances in autism: heterogeneity and convergence on shared pathways. Curr Opin Genet Dev. 2009;19:271–8.
Uchino S, Waga C. SHANK3 as an autism spectrum disorder-associated gene. Brain and Development. 2013;35:106–10.
Leblond CS, Nava C, Polge A, Gauthier J, Huguet G, Lumbroso S, Giuliano F, Stordeur C, Depienne C, Mouzat K, Pinto D. Meta-analysis of SHANK mutations in autism spectrum disorders: a gradient of severity in cognitive impairments. PLoS Genet. 2014;10:e1004580.
Lord C, Risi S, Lambrecht L, Cook Jr EH, Leventhal BL, DiLavore PC, et al. The autism diagnostic observation schedule—generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000;30:205–23.
Rutter M, Le Couteur A, Lord C. Autism diagnostic interview-revised. Los Angeles: Western Psychological Services; 2003.
Skuse DH. Rethinking the nature of genetic vulnerability to autistic spectrum disorders. Trends Genet. 2007;23:387–95.
Moss J, Howlin P. Autism spectrum disorders in genetic syndromes: implications for diagnosis, intervention and understanding the wider autism spectrum disorder population. J Intellect Disabil Res. 2009;53:852–73.
Richards C, Jones C, Groves L, Moss J, Oliver C. Prevalence of autism spectrum disorder phenomenology in genetic disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2015;2:909–16.
Moss J, Oliver C, Nelson L, Richards C, Hall S. Delineating the profile of autism spectrum disorder characteristics in Cornelia de Lange and fragile X syndromes. Am J Intellect Dev Disabil. 2013;118:55–73.
Moss J, Howlin P, Magiati I, Oliver C. Characteristics of autism spectrum disorder in Cornelia de Lange syndrome. J Child Psychol Psychiatry. 2012;53:883–91.
Philippe A, Boddaert N, Vaivre-Douret L, Robel L, Danon-Boileau L, Malan V, et al. Neurobehavioral profile and brain imaging study of the 22q13. 3 deletion syndrome in childhood. Pediatrics. 2008;122:e376–82.
Kushlick A, Blunden R, Cox G. A method of rating behavior characteristics for use in large scale surveys of mental handicap. Psychol Med. 1973;3:466–78.
Berument SK, Rutter M, Lord C, Pickles A, Bailey A. Autism Screening Questionnaire: diagnostic validity. Br J Psychiatry. 1999;175:444–51.
Rutter M, Bailey A, Lord C, Berument SK. The social communication questionnaire. Los Angeles: Western Psychological Services; 2003.
Bölte S, Poustka F. The relation between general cognitive level and adaptive behavior domains in individuals with autism with and without co-morbid mental retardation. Child Psychiatry Hum Dev. 2002;33:165–72.
Kanne SM, Gerber AJ, Quirmbach LM, Sparrow SS, Cicchetti DV, Saulnier CA. The role of adaptive behavior in autism spectrum disorders: implications for functional outcome. J Autism Dev Disord. 2011;41:1007–18.
Perry A, Flanagan HE, Geier JD, Freeman NL. Brief report: the Vineland Adaptive Behavior Scales in young children with autism spectrum disorders at different cognitive levels. J Autism Dev Disord. 2009;39:1066–78.
Palmer J, Jenkins J. The Wessex behavior rating system for mentally-handicapped people—reliability study. Brit. J Ment Subnorm. 1982;28:88–96.
Ross E, Oliver C. Mood, interest and pleasure and challenging behaviour. J Intellect Disabil Res. 2002;46:191–7.
Burbidge C, Oliver C, Moss J, Arron K, Berg K, Furniss F, et al. The association between repetitive behaviours, impulsivity and hyperactivity in people with intellectual disability. J Intellect Disabil Res. 2010;54:1078–92.
Moss J, Oliver C, Arron K, Burbidge C, Berg K. The prevalence and phenomenology of repetitive behavior in genetic syndromes. J Autism Dev Disord. 2009;39:572–88.
Howlin P, Karpf J. Using the social communication questionnaire to identify ‘autistic spectrum’ disorders associated with other genetic conditions: findings from a study of individuals with Cohen syndrome. Autism. 2004;8:175–82.
Charman T, Baird G, Simonoff E, Loucas T, Chandler S, Meldrum D, Pickles A. Efficacy of three screening instruments in the identification of autistic-spectrum disorders. Br J Psychiatry. 2007;191:554–9.
Oliver C, Berg K, Moss J, Arron K, Burbidge C. Delineation of behavioral phenotypes in genetic syndromes: characteristics of autism spectrum disorder, affect and hyperactivity. J Autism Dev Disord. 2011;41:1019–32.
Breau L, Camfield CS, McGrath PJ, Finley A. The incidence of pain in children with severe cognitive impairments. Arch Pediatr Adolesc Med. 2003;157:1219–26.
Carr EG, JS O-DS. Physical illness, pain and problem behavior in minimally verbal people with developmental disabilities. J Autism Dev Disord. 2007;37:413–24.
Luzzani S, Macchini F, Valade A, Milani D, Selicorni A. Gastroesophageal reflux and Cornelia de Lange syndrome: typical and atypical symptoms. Am J Med Genet Part A. 2003;119A:283–7.
Bariselli S, Tzanoulinou S, Glangetas C, Prévost-Solié C, Pucci L, Viguié J, et al. SHANK3 controls maturation of social reward circuits in the VTA. Nat Neurosci. 2016;19:926–34.
Costales JL, Kolevzon A. Phelan–McDermid syndrome and SHANK3: implications for treatment. Neurotherapeutics. 2015;12:620–30.